Founders

See also: People > Board Members

Andrew J. Stewart Coats

Board Director

MA(Oxon) MBBChir (Cantab) DM (Oxon) DSc FRACP FRCP FESC FACC FAHA FHFA FAICD MIoD, MBA (London Business School)


Professor Andrew Coats MBA, DSc, DM, co-founded Actimed Therapeutics in 2017, having previously founded Myotec (later renamed PsiOxus Therapeutics). He has over 30 years of experience as an academic manager, having been both Dean of Medicine and Deputy Vice-Chancellor at the University of Sydney and head of Clinical Cardiology at Imperial College and the Royal Brompton Hospital in London.

Prof. Coats also served as CEO of the Norwich Research Park in the UK. He is an experienced board director with an MBA from London Business School and over 20 years of experience of company boards in roles including audit, remuneration, nominations and governance committees in biotechnology, health care and education, including the George Institute of International Health, the Woolcock Institute, Lone Star Heart, Myotec, PsiOxus, and Faraday (Australia). He has over 600 research papers, 85,000 citations and an H-Index of 125.

 
 

See also: People > Board Members

Stefan D. Anker

Chairman of the scientific advisory board

MD, PhD, FESC


Professor Stefan Anker MD, PhD, co-founded Actimed Therapeutics in 2017, having previously founded Myotec (later renamed PsiOxus Therapeutics). Prof Anker has 25 years academic research experience in heart failure, cachexia and clinical trials with positions at Royal Brompton Hospital and Imperial College in London as well as University Göttingen and Charité Berlin. He has been a tenured University professor in Germany since 2007, leading a highly active research group, and he is founder Editor-in-Chief of two successful scientific journals (amongst them the Journal of Cachexia, Sarcopenia and Muscle). Prof Anker was Vice President of the European Society of Cardiology (ESC) from 2016 to 2018, serving on the ESC board from 2012 to 2018. He has served on the board of the Heart Failure Association (HFA) of the ESC since 2006; he was HFA President from 2012 to 2014. Dr Anker is the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders which he has held since 2008 (SCWD – see www.cachexia.org). Dr Anker was and is a member of over 30 international clinical trial steering committees, currently chairing or co-chairing 6 trials in phase II / III / IV. In this context, Dr Anker has significant experience interacting with regulators in different branches of the FDA and EMA. Dr Anker has over 800 research papers, 118,000 citations and an H-Index of 142.


Andrew J. Stewart Coats

Board Director

MA(Oxon) MBBChir (Cantab) DM (Oxon) DSc FRACP FRCP FESC FACC FAHA FHFA FAICD MIoD, MBA (London Business School)


Professor Andrew Coats MBA, DSc, DM, co-founded Actimed Therapeutics in 2017, having previously founded Myotec (later renamed PsiOxus Therapeutics). He has over 30 years of experience as an academic manager, having been both Dean of Medicine and Deputy Vice-Chancellor at the University of Sydney and head of Clinical Cardiology at Imperial College and the Royal Brompton Hospital in London.

Prof. Coats also served as CEO of the Norwich Research Park in the UK. He is an experienced board director with an MBA from London Business School and over 20 years of experience of company boards in roles including audit, remuneration, nominations and governance committees in biotechnology, health care and education, including the George Institute of International Health, the Woolcock Institute, Lone Star Heart, Myotec, PsiOxus, and Faraday (Australia). He has over 600 research papers, 85,000 citations and an H-Index of 125.

 
 

See also: People > Board Members


Stefan D. Anker

Chairman of the scientific advisory board

MD, PhD, FESC


Professor Stefan Anker MD, PhD, co-founded Actimed Therapeutics in 2017, having previously founded Myotec (later renamed PsiOxus Therapeutics). Prof Anker has 25 years academic research experience in heart failure, cachexia and clinical trials with positions at Royal Brompton Hospital and Imperial College in London as well as University Göttingen and Charité Berlin. He has been a tenured University professor in Germany since 2007, leading a highly active research group, and he is founder Editor-in-Chief of two successful scientific journals (amongst them the Journal of Cachexia, Sarcopenia and Muscle). Prof Anker was Vice President of the European Society of Cardiology (ESC) from 2016 to 2018, serving on the ESC board from 2012 to 2018. He has served on the board of the Heart Failure Association (HFA) of the ESC since 2006; he was HFA President from 2012 to 2014. Dr Anker is the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders which he has held since 2008 (SCWD – see www.cachexia.org). Dr Anker was and is a member of over 30 international clinical trial steering committees, currently chairing or co-chairing 6 trials in phase II / III / IV. In this context, Dr Anker has significant experience interacting with regulators in different branches of the FDA and EMA. Dr Anker has over 800 research papers, 118,000 citations and an H-Index of 142.

... cachexia represents an important unmet need.”

"... cachexia represents an important unmet need.”

 

Please click here to contact Actimed Therapeutics